TIDMCLIN

RNS Number : 4619X

Clinigen Group plc

24 November 2017

24 November 2017

Director's Share Dealing

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the global pharmaceutical and services group, announces that it was notified on 23 November 2017 that the following transaction took place on 23 November 2017.

Chris Rigg, Chief Business Officer, sold 4,955 ordinary shares of 0.1 pence each in the Company at a price of 1017 pence per share.

Following this transaction, Mr Rigg's total beneficial interest in the Company is 1,608 ordinary shares, representing less than 0.01 per cent of Clinigen's current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging 
        managerial responsibilities/person 
        closely associated 
----  ------------------------------------------------------- 
 a)    Name                    Chris Rigg 
----  ----------------------  ------------------------------- 
 2     Reason for the notification 
----  ------------------------------------------------------- 
 a)    Position/status         Chief Business Officer 
----  ----------------------  ------------------------------- 
 b)    Initial                 Initial Notification 
        notification 
        /Amendment 
----  ----------------------  ------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, 
        auctioneer or auction monitor 
----  ------------------------------------------------------- 
 a)    Name                    Clinigen Group plc 
----  ----------------------  ------------------------------- 
 b)    Legal Entity            N/A 
        Identifier 
----  ----------------------  ------------------------------- 
 4     Details of the transaction(s): section 
        to be repeated for (i) each type 
        of instrument; (ii) each type of 
        transaction; (iii) each date; and 
        (iv) each place where transactions 
        have been conducted 
----  ------------------------------------------------------- 
 a)    Description             Ordinary shares of 0.1 pence 
        of the financial        each 
        instrument,             GB00B89J2419 
        type of 
        instrument 
        Identification 
        code 
----  ----------------------  ------------------------------- 
 b)    Nature of               Sale of shares 
        the transaction 
----  ----------------------  ------------------------------- 
 c)    Currency                GBP 
----  ----------------------  ------------------------------- 
 d)    Price(s)                  Price(s)        Volume(s) 
        and volume(s) 
----  ----------------------  --------------  --------------- 
                                   1017p           4,955 
 ---------------------------  --------------  --------------- 
 
 e)    Aggregated               4,955 
        information 
   - Aggregated                  1017p 
    volume 
   - Price                       GBP50,392 
   - Aggregated 
    total 
 ---------------------------  ------------------------------- 
 f)    Date of                 23 November 2017 
        the transaction 
----  ----------------------  ------------------------------- 
 g)    Place of                London Stock Exchange, AIM 
        the transaction 
----  ----------------------  -------------------------------

-Ends-

Contact Details

 
 Clinigen Group plc                     Tel: +44 (0) 1283 
                                         495 010 
 Shaun Chilton, Group Chief 
  Executive Officer 
  Martin Abell, Group Chief Financial 
  Officer 
 
 Numis Securities Limited               Tel: +44 (0) 20 
                                         7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 RBC Capital Markets - Joint            Tel: +44 (0) 20 
  Broker                                 7653 4000 
 Marcus Jackson / Elliot Thomas 
  / Jack Wood 
 
 Instinctif Partners (media             Tel: +44 (0) 20 
  relations)                             7457 2020 
 Melanie Toyne-Sewell / Alex 
  Shaw / Deborah Bell                   Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLIFFALFLSFID

(END) Dow Jones Newswires

November 24, 2017 04:26 ET (09:26 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Clinigen Charts.
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Clinigen Charts.